Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response

被引：0
|
作者：
Saad, F [1 ]
机构：
[1] Univ Montreal, Dept Urol Surg, Ctr Hosp, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 01期
关键词：
D O I：
10.1093/jnci/dji017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [1] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response
    Saad, F
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1480 - 1481
  • [2] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Grenader, T
    Shavit, L
    Uziely, B
    Peretz, T
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03) : 235 - 236
  • [3] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Parker, CC
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19) : 1480 - 1480
  • [4] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Tanvetyanon, T
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01): : 70 - 70
  • [5] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Chin, JL
    Vinholes, JJ
    Goas, JA
    Zheng, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) : 879 - 882
  • [6] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [7] Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Smith, Matthew R.
    Cook, Richard J.
    Coleman, Robert
    Brown, Janet
    Lipton, Allan
    Major, Pierre
    Hei, Yong Jiang
    Saad, Fred
    UROLOGY, 2007, 70 (02) : 315 - 319
  • [8] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response
    Saad, F
    Gleason, DM
    Murray, R
    Goas, JA
    Chen, B
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (04) : 333 - 334
  • [9] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response
    Saad, F
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) : 1183 - 1184
  • [10] Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response
    Saad, F
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (15) : 1175 - 1175
12345